幕上高级别胶质瘤的放疗与硝基咪唑类药物：第二项临床试验
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.
作者信息
Urtasun R, Feldstein M L, Partington J, Tanasichuk H, Miller J D, Russell D B, Agboola O, Mielke B
出版信息
Br J Cancer. 1982 Jul;46(1):101-8. doi: 10.1038/bjc.1982.171.
Abstract
As a continuation of a previous controlled trial using "high-dose" metronidazole as a specific sensitizer of hypoxic cells, we used a more efficient nitroimidazole derivative (misonidazole, MISO) in combination with higher doses of radiation in patients with supratentorial high-grade astrocytomas. Sixty-six patients were stratified according to functional level and histological grading, and randomly allocated within 2 weeks of operation of 1 of 3 therapeutic groups: 1, conventional radiation alone; 2, large fractions of radiation with high-dose metronidazole; and 3, radiation as in Group 2 but with equitoxic doses of MISO. We examined survival as the principal end-point of the study. Neither by increasing the dose of radiation over the previous study, nor by using a more efficient sensitizer, were we able to improve survival over the current conventional daily fractionated radiation.
摘要
作为之前一项对照试验的延续，该试验使用“高剂量”甲硝唑作为缺氧细胞的特异性增敏剂，我们在幕上高级别星形细胞瘤患者中使用了一种更有效的硝基咪唑衍生物（米索硝唑，MISO），并联合更高剂量的放疗。66例患者根据功能水平和组织学分级进行分层，并在术后2周内随机分配到3个治疗组中的1组：1. 单纯常规放疗；2. 大分割放疗联合高剂量甲硝唑；3. 与第2组放疗相同，但使用等效毒性剂量的米索硝唑。我们将生存期作为研究的主要终点。无论是比之前的研究增加放疗剂量，还是使用更有效的增敏剂，我们都未能在当前的常规每日分次放疗基础上提高生存期。
相似文献
1
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.幕上高级别胶质瘤的放疗与硝基咪唑类药物：第二项临床试验
Br J Cancer. 1982 Jul;46(1):101-8. doi: 10.1038/bjc.1982.171.
2
A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. A report from the MRC Working Party on misonidazole in gliomas.米索硝唑联合放疗治疗3级和4级星形细胞瘤的疗效研究。医学研究委员会胶质瘤米索硝唑工作组的报告。
Br J Radiol. 1983 Sep;56(669):673-82. doi: 10.1259/0007-1285-56-669-673.
3
Misonidazole combined with hyperfractionation in the management of malignant glioma.米索硝唑联合超分割放疗在恶性胶质瘤治疗中的应用
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1709-12. doi: 10.1016/0360-3016(84)90533-9.
4
Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.3级和4级手术切除星形细胞瘤的综合治疗。米索硝唑与两种不同放疗方案及后续洛莫司汀化疗的前瞻性随机研究。斯堪的纳维亚胶质母细胞瘤研究组前瞻性多中心试验的第二阶段。
Cancer. 1985 Jul 1;56(1):41-7. doi: 10.1002/1097-0142(19850701)56:1<41::aid-cncr2820560108>3.0.co;2-w.
5
Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna Study Group.米索硝唑与放疗联合治疗高级别星形细胞瘤：维也纳研究小组的进一步报告
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1713-7. doi: 10.1016/0360-3016(84)90534-0.
6
A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.米索硝唑与放疗治疗3级和4级脑星形细胞瘤的随机研究。
Br J Cancer. 1981 Apr;43(4):436-42. doi: 10.1038/bjc.1981.64.
7
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.抗癌药物与米索硝唑或甲硝唑在体内的相互作用：环磷酰胺和卡莫司汀。
Br J Cancer. 1980 Dec;42(6):871-80. doi: 10.1038/bjc.1980.335.
8
Comparative study of thermoradiosensitization by misonidazole and metronidazole in vivo: antitumour effect and pharmacokinetics.米索硝唑与甲硝唑体内热放射增敏作用的比较研究：抗肿瘤效果与药代动力学
Int J Hyperthermia. 1992 Sep-Oct;8(5):645-58. doi: 10.3109/02656739209038000.
9
Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.小鼠肿瘤对洛莫司汀与米索硝唑及其他辐射增敏剂联合用药的反应。
Br J Cancer. 1982 Feb;45(2):272-81. doi: 10.1038/bjc.1982.43.
10
Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report.多次每日分割放射治疗与米索硝唑治疗恶性星形细胞瘤的初步报告
Cancer. 1985 Aug 15;56(4):758-60. doi: 10.1002/1097-0142(19850815)56:4<758::aid-cncr2820560410>3.0.co;2-2.
引用本文的文献
1
Molecular mechanisms of tumor resistance to radiotherapy.肿瘤放疗抵抗的分子机制。
Mol Cancer. 2023 Jun 15;22(1):96. doi: 10.1186/s12943-023-01801-2.
2
Targeting Hypoxia: Revival of Old Remedies.靶向缺氧：旧药新用。
Biomolecules. 2021 Oct 29;11(11):1604. doi: 10.3390/biom11111604.
3
Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas.缺氧、代谢与生物钟：克服高级别脑胶质瘤辐射抵抗的新关联。
J Exp Clin Cancer Res. 2020 Jul 7;39(1):129. doi: 10.1186/s13046-020-01639-2.
4
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.老年新诊断胶质母细胞瘤的治疗：一项网状Meta分析
Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. doi: 10.1002/14651858.CD013261.pub2.
5
Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole and .与多拉硝唑相比，吉西他唑缺氧放射增敏作用的临床前研究。 （原文结尾处的“and.”表述有误，可能影响准确理解，以上是按照修正后的理解进行翻译）
Oncol Lett. 2018 Feb;15(2):1993-1998. doi: 10.3892/ol.2017.7481. Epub 2017 Nov 23.
6
Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.立体定向消融放疗应与乏氧细胞放射增敏剂联合应用。
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):323-7. doi: 10.1016/j.ijrobp.2010.04.070.
7
Metastatic seeding of the stereotactic biopsy tract in glioblastoma multiforme: case report and review of the literature.多形性胶质母细胞瘤立体定向活检通道的转移播散：病例报告及文献复习
J Neurooncol. 2001 Dec;55(3):167-71. doi: 10.1023/a:1013873431159.
8
Recognition and management of gliomas.胶质瘤的识别与管理
Drugs. 1997 Feb;53(2):235-44. doi: 10.2165/00003495-199753020-00004.
9
10
Studies of the pharmacokinetic properties of nimorazole.尼莫唑的药代动力学特性研究。
Br J Cancer. 1983 Jul;48(1):27-34. doi: 10.1038/bjc.1983.153.
本文引用的文献
1
A toxicity study of daily dose metronidazole with pelvic irradiation.每日剂量甲硝唑与盆腔照射的毒性研究。
Cancer Clin Trials. 1980 Fall;3(3):223-30.
2
Drug interactions with misonidazole: effects of dexamethasone and its derivatives on the pharmacokinetics and toxicity of misonidazole in mice.药物与米索硝唑的相互作用：地塞米松及其衍生物对小鼠体内米索硝唑药代动力学和毒性的影响
Biochem Pharmacol. 1980 Oct 15;29(20):2769-76. doi: 10.1016/0006-2952(80)90010-6.
3
Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials.脑肿瘤化疗：对目前用于II期和III期试验的药物的评估。
Cancer Treat Rep. 1980;64(12):1179-205.
4
The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies.米索硝唑与放射治疗联合应用的剑桥胶质瘤试验及相关药代动力学研究。
Cancer Clin Trials. 1980 Fall;3(3):267-73.
5
Clinical experience with misonidazole: high dose fractions versus daily low doses.米索硝唑的临床经验：高剂量分次给药与每日低剂量给药对比
Cancer Clin Trials. 1980 Summer;3(2):179-86.
6
Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.米索硝唑周围神经病变：其与血药浓度及其他药物的关系。
Cancer Clin Trials. 1980 Summer;3(2):105-9.
7
The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethasone.米索硝唑的神经毒性：苯妥英钠和地塞米松的潜在调节作用。
Br J Radiol. 1980 Feb;53(626):172-3. doi: 10.1259/0007-1285-53-626-172.
8
Letter: "High-dose" metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials.信函：“高剂量”甲硝唑：在临床放射治疗试验中进行研究性使用之前的初步药理学研究。
Br J Radiol. 1974 May;47(557):297-9. doi: 10.1259/0007-1285-47-557-297-c.
9
Effectiveness of nitrofuran derivatives in sensitizing hypoxic mammalian cells to x rays.硝基呋喃衍生物使缺氧哺乳动物细胞对X射线敏感的有效性。
Br J Radiol. 1973 Aug;46(548):623-30. doi: 10.1259/0007-1285-46-548-623.
10
Metronidazole ("Flagyl"). A radiosensitizer of hypoxic cells.甲硝唑（“灭滴灵”）。一种缺氧细胞的放射增敏剂。
Br J Radiol. 1974 Aug;47(560):474-81. doi: 10.1259/0007-1285-47-560-474.
Zotero 插件